Patricia J Rodriguez, Brianna M Goodwin Cartwright, Samuel Gratzl, Rajdeep Brar, Charlotte Baker, Ty J. Gluckman, Nicholas L Stucky
{"title":"Comparative Effectiveness of Semaglutide and Tirzepatide for Weight Loss in Adults with Overweight and Obesity in the US: A Real-World Evidence Study","authors":"Patricia J Rodriguez, Brianna M Goodwin Cartwright, Samuel Gratzl, Rajdeep Brar, Charlotte Baker, Ty J. Gluckman, Nicholas L Stucky","doi":"10.1101/2023.11.21.23298775","DOIUrl":null,"url":null,"abstract":"<strong>Background</strong> Both tirzepatide and semaglutide have been shown to reduce weight for patients with overweight or obesity in randomized controlled trials (RCTs). While tirzepatide appears to provide greater weight loss than semaglutide in this population, head-to-head RCTs are not yet available. Accordingly, we sought to compare on-treatment weight loss in a real-world setting for adults with overweight or obesity initiated on tirzepatide or semaglutide.","PeriodicalId":501023,"journal":{"name":"medRxiv - Primary Care Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Primary Care Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2023.11.21.23298775","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background Both tirzepatide and semaglutide have been shown to reduce weight for patients with overweight or obesity in randomized controlled trials (RCTs). While tirzepatide appears to provide greater weight loss than semaglutide in this population, head-to-head RCTs are not yet available. Accordingly, we sought to compare on-treatment weight loss in a real-world setting for adults with overweight or obesity initiated on tirzepatide or semaglutide.